Cargando…
A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
A 44-year-old woman presented with lower abdominal pain and bilateral ovarian masses on ultrasound. Exploratory laparotomy revealed extensive peritoneal and intra-abdominal disease and an abnormal appendix. Bilateral salpingo-oophorectomy, infracolic omentectomy, ileocolic resection and primary anas...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918857/ https://www.ncbi.nlm.nih.gov/pubmed/20740172 http://dx.doi.org/10.1159/000229245 |
_version_ | 1782185155330310144 |
---|---|
author | Powell, Erin D. Macdonald, D. Blair Elkeilani, Akram M. Asmis, Timothy R. |
author_facet | Powell, Erin D. Macdonald, D. Blair Elkeilani, Akram M. Asmis, Timothy R. |
author_sort | Powell, Erin D. |
collection | PubMed |
description | A 44-year-old woman presented with lower abdominal pain and bilateral ovarian masses on ultrasound. Exploratory laparotomy revealed extensive peritoneal and intra-abdominal disease and an abnormal appendix. Bilateral salpingo-oophorectomy, infracolic omentectomy, ileocolic resection and primary anastomosis were performed. Final pathology revealed a primary appendiceal adenocarcinoma, poorly differentiated, of signet ring cell type. CT scan postoperatively revealed gross residual disease. The patient was treated with FOLFOX chemotherapy combined with bevacizumab. Repeat CT scan showed a decrease in residual disease and the patient clinically improved. After her treatment has been continued for 13 months, she remains clinically well and her CT scan shows sustained disease stability. Disseminated appendiceal carcinoma is generally considered to be refractory to 5-FU-based chemotherapy and, to our knowledge, this is the first reported case of a patient with appendiceal adenocarcinoma demonstrating clinical benefit and sustained stability of disease with combination chemotherapy plus bevacizumab. |
format | Text |
id | pubmed-2918857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-29188572010-08-25 A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab Powell, Erin D. Macdonald, D. Blair Elkeilani, Akram M. Asmis, Timothy R. Case Rep Oncol Published: July 2009 A 44-year-old woman presented with lower abdominal pain and bilateral ovarian masses on ultrasound. Exploratory laparotomy revealed extensive peritoneal and intra-abdominal disease and an abnormal appendix. Bilateral salpingo-oophorectomy, infracolic omentectomy, ileocolic resection and primary anastomosis were performed. Final pathology revealed a primary appendiceal adenocarcinoma, poorly differentiated, of signet ring cell type. CT scan postoperatively revealed gross residual disease. The patient was treated with FOLFOX chemotherapy combined with bevacizumab. Repeat CT scan showed a decrease in residual disease and the patient clinically improved. After her treatment has been continued for 13 months, she remains clinically well and her CT scan shows sustained disease stability. Disseminated appendiceal carcinoma is generally considered to be refractory to 5-FU-based chemotherapy and, to our knowledge, this is the first reported case of a patient with appendiceal adenocarcinoma demonstrating clinical benefit and sustained stability of disease with combination chemotherapy plus bevacizumab. S. Karger AG 2009-07-17 /pmc/articles/PMC2918857/ /pubmed/20740172 http://dx.doi.org/10.1159/000229245 Text en Copyright © 2009 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions. |
spellingShingle | Published: July 2009 Powell, Erin D. Macdonald, D. Blair Elkeilani, Akram M. Asmis, Timothy R. A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab |
title | A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab |
title_full | A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab |
title_fullStr | A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab |
title_full_unstemmed | A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab |
title_short | A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab |
title_sort | case of appendiceal adenocarcinoma with clinical benefit from folfox and bevacizumab |
topic | Published: July 2009 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918857/ https://www.ncbi.nlm.nih.gov/pubmed/20740172 http://dx.doi.org/10.1159/000229245 |
work_keys_str_mv | AT powellerind acaseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT macdonalddblair acaseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT elkeilaniakramm acaseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT asmistimothyr acaseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT powellerind caseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT macdonalddblair caseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT elkeilaniakramm caseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT asmistimothyr caseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab |